3.270 articles found

Correction: Measuring Physical Functioning Using Wearable Sensors in Parkinson Disease and Chronic Obstructive Pulmonary Disease (the Accuracy of Digital Assessment of Performance Trial Study): Protocol for a Prospective Observational Study.

de Graaf D, de Vries NM, van de Zande T, Schimmel JJP, Shin S, Kowahl N, Barman P, Kapur R, Marks WJ, van 't Hul A, Bloem BR.

JMIR Res Protoc · 2024-12-09

DOI: 10.2196/68647PMID: 39652853

Wearable Surface Electromyography System to Predict Freeze of Gait in Parkinson's Disease Patients.

Moore A, Li J, Contag CH, Currano LJ, Pyles CO, Hinkle DA, Patil VS.

Sensors (Basel) · 2024-12-09

DOI: 10.3390/s24237853PMID: 39686390

Exploration of Novel Biomarkers for Neurodegenerative Diseases Using Proteomic Analysis and Ligand-Binding Assays.

Kenzelmann A, Boch C, Schmidt R, Richter M, Schulz M.

Biomedicines · 2024-12-09

DOI: 10.3390/biomedicines12122794PMID: 39767701

Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis.

Vo DK, Trinh KTL.

Int J Mol Sci · 2024-12-08

DOI: 10.3390/ijms252313190PMID: 39684900

Plasma circulating cell-free DNA integrity and relative telomere length as diagnostic biomarkers for Parkinson's disease and multiple system atrophy: a cross-sectional study.

Ying C, Han C, Li Y, Zhang M, Xiao S, Zhao L, Zhang H, Yu Q, An J, Mao W, Cai Y.

Neural Regen Res · 2024-12-07

DOI: 10.4103/nrr.nrr-d-24-00599PMID: 39665795

Perceptions of digitally supported home exercise for people with Parkinson's disease: A qualitative study.

Sedhed J, Johansson H, Åkesson E, Franzén E, Leavy B.

Clin Rehabil · 2024-12-05

DOI: 10.1177/02692155241298859PMID: 39632720

Patient perspectives on the use of digital medical devices and health data for AI-driven personalised medicine in Parkinson's Disease.

Paccoud I, Valero MM, Marín LC, Bontridder N, Ibrahim A, Winkler J, Fomo M, Sapienza S, Khoury F, Corvol JC, Fröhlich H, Klucken J.

Front Neurol · 2024-12-04

DOI: 10.3389/fneur.2024.1453243PMID: 39697442

An innovative cellular medicine approach via the utilization of novel nanotechnology-based biomechatronic platforms as a label-free biomarker for early melanoma diagnosis.

Alqabandi JA, David R, Abdel-Motal UM, ElAbd RO, Youcef-Toumi K.

Sci Rep · 2024-12-03

DOI: 10.1038/s41598-024-79154-zPMID: 39627312

Machine Learning for Early Detection of Cognitive Decline in Parkinson's Disease Using Multimodal Biomarker and Clinical Data.

Mohammadi R, Ng SYE, Tan JY, Ng ASL, Deng X, Choi X, Heng DL, Neo S, Xu Z, Tay KY, Au WL, Tan EK, Tan LCS, Steyerberg EW, Greene W, Saffari SE.

Biomedicines · 2024-12-03

DOI: 10.3390/biomedicines12122758PMID: 39767666

GENETIC AND SEROLOGICAL BIOMARKERS AS PREDICTORS OF PARKINSON’S DISEASE COGNITIVE IMPAIRMENT: A SYSTEMATIC REVIEW

Check source for author details

Innovation in aging · 2024-12-01

Multimodal neuroimaging and plasma biomarker evidence of white matter macrostructure loss in Parkinson's dementia

Zarkali A, Hannaway N, McColgan P, Heslegrave A, Veleva E, Laban R, Zetterberg H, Lees A, Fox N, Weil R.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024-12-01

Characterization and Evaluation of Alpha‐Synuclein Aggregates: Unveiling Their Potential as a Biomarker for Parkinson's Disease (PD)

Debarnot C, Challagundla M, Kleinert C, Schulz M, Henn C, Boehm N, Richter M.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024-12-01